Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating their protein-based vaccine technology. The approval positions Novavax as the ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

The vaccine is expected to be commercially ready for the 2025-2026 COVID-19 season. The Food and Drug Administration (FDA) has approved Nuvaxovid ™ (COVID-19 Vaccine, Adjuvanted) for active ...

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age. The FDA has granted full approval to Novavax’s COVID-19 vaccine, Nuvaxovid, for ...

Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine, and shares jumped 25% at the opening bell Monday.

Novavax shares rose in premarket trading after disclosing that the Food and Drug Administration approved an application for Covid-19 treatment Nuvaxovid. Shares rose 10% to $7.41 in premarket ...

The vaccine, called Nuvaxovid, is mainly intended for adults 65 or older. But people ages 12 to 64 with medical conditions that increase their risk of serious illness from COVID can also get the shot.

As the World Health Organization initiates a new agreement for coordinating global responses to future pandemics, the future ...

Novavax, Inc. announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Nuvaxovid for active immunization to prevent coronavirus disease 2019 ...

The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, ...

Novavax, Inc. (NASDAQ:NVAX), currently trading at $6.73 and showing strong profitability with a gross margin of 58%, has received approval from the U.S. Food and Drug Administration (FDA) for its ...